Distortion in Heat Treated Tube: A Materials Engineering Approach

Problem: A tube heat treater was making heavily distorted tubes with “hooked” ends on their induction heat treating line. The first and last meter of every tube was more than 1cm out of straightness. Hypothesis: Non-uniform phase transformation can occur from asymmetric heating and cooling, and the observed distortion is due to asymmetric heating and cooling during heat treatment of the tube

High-Temperature Interactions Between Titanium Alloys And Strontium Zirconate Refractories

We investigated interactions between Ti6Al4V alloys and strontium zirconate (SrZrO3) ceramic to assess its potential as a refractory mold material in investment casting. We developed a robust yet simple procedure to examine both the liquid–solid and solid–solid interactions using pellets in drop casting and diffusion couple methods. Reaction layers were characterized using optical microscopy, scanning electron microscopy (SEM), transmission electron microscopy (TEM), and x-ray diffraction (XRD). The results were compared to alumina (Al2O3) which is still a common refractory ceramic for molds in investment casting. Our findings indicate that Ti6Al4V surfaces in contact with SrZrO3 had no apparent changes in surface chemistry nor microstructure. On the other hand, Ti6Al4V surfaces in contact with Al2O3 developed γ-TiAl and α 2-Ti3Al intermetallics with thicknesses of ~ 100 μm in diffusion couples and ~ 10 μm in drop-casting experiments. Nanoindentation results showed that the surface of Ti6Al4V in contact with Al2O3 was significantly harder compared to SrZrO3, confirming our conclusion. Given the time and costs associated with mechanical and chemical removal of reaction layers on Ti6Al4V castings, SrZrO3 can be a better choice for a mold material in the investment casting of titanium alloys

Effect of transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause mortality in patients with aortic stenosis

Importance: Transcatheter aortic valve implantation (TAVI) is a less invasive alternative to surgical aortic valve replacement and is the treatment of choice for patients at high operative risk. The role of TAVI in patients at lower risk is unclear. Objective: To determine whether TAVI is noninferior to surgery in patients at moderately increased operative risk. Design, Setting, and Participants: In this randomized clinical trial conducted at 34 UK centers, 913 patients aged 70 years or older with severe, symptomatic aortic stenosis and moderately increased operative risk due to age or comorbidity were enrolled between April 2014 and April 2018 and followed up through April 2019. Interventions: TAVI using any valve with a CE mark (indicating conformity of the valve with all legal and safety requirements for sale throughout the European Economic Area) and any access route (n = 458) or surgical aortic valve replacement (surgery; n = 455). Main Outcomes and Measures: The primary outcome was all-cause mortality at 1 year. The primary hypothesis was that TAVI was noninferior to surgery, with a noninferiority margin of 5% for the upper limit of the 1-sided 97.5% CI for the absolute between-group difference in mortality. There were 36 secondary outcomes (30 reported herein), including duration of hospital stay, major bleeding events, vascular complications, conduction disturbance requiring pacemaker implantation, and aortic regurgitation. Results: Among 913 patients randomized (median age, 81 years [IQR, 78 to 84 years]; 424 [46%] were female; median Society of Thoracic Surgeons mortality risk score, 2.6% [IQR, 2.0% to 3.4%]), 912 (99.9%) completed follow-up and were included in the noninferiority analysis. At 1 year, there were 21 deaths (4.6%) in the TAVI group and 30 deaths (6.6%) in the surgery group, with an adjusted absolute risk difference of −2.0% (1-sided 97.5% CI, −∞ to 1.2%; P < .001 for noninferiority). Of 30 prespecified secondary outcomes reported herein, 24 showed no significant difference at 1 year. TAVI was associated with significantly shorter postprocedural hospitalization (median of 3 days [IQR, 2 to 5 days] vs 8 days [IQR, 6 to 13 days] in the surgery group). At 1 year, there were significantly fewer major bleeding events after TAVI compared with surgery (7.2% vs 20.2%, respectively; adjusted hazard ratio [HR], 0.33 [95% CI, 0.24 to 0.45]) but significantly more vascular complications (10.3% vs 2.4%; adjusted HR, 4.42 [95% CI, 2.54 to 7.71]), conduction disturbances requiring pacemaker implantation (14.2% vs 7.3%; adjusted HR, 2.05 [95% CI, 1.43 to 2.94]), and mild (38.3% vs 11.7%) or moderate (2.3% vs 0.6%) aortic regurgitation (adjusted odds ratio for mild, moderate, or severe [no instance of severe reported] aortic regurgitation combined vs none, 4.89 [95% CI, 3.08 to 7.75]). Conclusions and Relevance: Among patients aged 70 years or older with severe, symptomatic aortic stenosis and moderately increased operative risk, TAVI was noninferior to surgery with respect to all-cause mortality at 1 year. Trial Registration: isrctn.com Identifier: ISRCTN57819173